Financial Performance - First-quarter 2025 revenues totaled $13.7 billion, a decrease of 8% compared to $14.9 billion in the prior-year quarter[5] - Reported diluted EPS for the first quarter of 2025 was $0.52, down 5% from $0.55 in the same quarter of 2024, while adjusted diluted EPS increased by 12% to $0.92[5][4] - The global biopharmaceuticals business reported revenues of $13.4 billion, an 8% decline from $14.6 billion in the previous year[6] - The company reaffirmed its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion and adjusted diluted EPS between $2.80 and $3.00[7] - Total revenues for Q1 2025 were $13.715 billion, a decrease of 8% compared to $14.879 billion in Q1 2024[26] - Product revenues decreased by 9% to $11.294 billion in Q1 2025 from $12.443 billion in Q1 2024[26] - Alliance revenues were $2.113 billion, down 3% from $2.172 billion in the previous year[26] - Net income attributable to Pfizer Inc. common shareholders was $2.967 billion, a decrease of 5% from $3.115 billion in Q1 2024[26] - Earnings per share (EPS) for Q1 2025 were $0.52, down 5% from $0.55 in Q1 2024[26] - Total revenues for 2025 were $13,715 million, a decrease of 8% compared to 2024[43] Cost Savings and Efficiency - Pfizer is on track to achieve approximately $4.5 billion in net cost savings by the end of 2025, with additional productivity gains expected through 2027[4] - Pfizer announced approximately $1.2 billion in additional anticipated savings from its ongoing cost realignment program, expected to be achieved by the end of 2027[19] - The company expects total net cost savings of approximately $5.7 billion from the cost realignment program through 2027[19] - Pfizer expects approximately $4.5 billion in net cost savings from its ongoing cost realignment program by the end of 2025[4] - The company expects one-time costs to achieve additional savings to total approximately $1.6 billion, primarily for severance and digital enablement[19] Research and Development - R&D expenses for the first quarter of 2025 were $2.2 billion, a decrease of 12% compared to the prior year, reflecting a focus on pipeline optimization[12] - Research and development expenses decreased by 12% to $2.203 billion in Q1 2025 from $2.493 billion in Q1 2024[26] - The Phase 3 CREST trial of sasanlimab showed a 32% reduction in the risk of disease-related events compared to standard of care in high-risk non-muscle invasive bladder cancer patients[18] - The Phase 3 VERITAC-2 trial demonstrated a statistically significant improvement in progression-free survival for vepdegestrant compared to fulvestrant in the ESR1m population[18] Product Performance - Paxlovid revenues decreased by 75% year-over-year, primarily due to lower COVID-19 infections and the non-recurrence of a favorable adjustment from the previous year[13] - Vyndaqel family revenues increased by 33% operationally, driven by strong demand in the U.S. and international markets[11] - Primary Care revenues fell by 21% to $5,696 million, with significant declines in key products like Paxlovid, which dropped 76% to $491 million[43] - Specialty Care revenues increased by 4% to $3,987 million, driven by the Vyndaqel family, which saw a 31% increase to $1,486 million[43] - Oncology revenues rose by 6% to $3,758 million, with Ibrance revenues decreasing by 7% to $977 million[43] - Total alliance revenues decreased by 3% to $2,113 million, while total royalty revenues increased by 16% to $308 million[43] Tax and Income - The effective tax rate on adjusted income for the first quarter of 2025 was 7.8%, down from 16.6% in the prior year[15] - The effective tax rate for income from continuing operations was -6.8% in Q1 2025, compared to 8.6% in Q1 2024[32] - GAAP reported net income for Q1 2025 was $953 million, a decrease from $3,115 million in Q1 2024, representing a decline of approximately 69%[37] - Non-GAAP adjusted net income for Q1 2025 was $5,237 million, compared to $4,674 million in Q1 2024, indicating an increase of about 12%[37] - Earnings per share attributable to Pfizer Inc. common shareholders for Q1 2025 was $0.92, up from $0.82 in Q1 2024, reflecting a growth of approximately 12%[37] Strategic Initiatives and Risks - Pfizer's acquisition of Seagen in December 2023 is expected to enhance growth opportunities and market presence[48] - The company is implementing a Manufacturing Optimization Program aimed at reducing costs and improving efficiency[48] - Pfizer's financial guidance remains subject to significant uncertainties, including regulatory approvals and market dynamics[49] - The company faces risks related to competition from new product entrants, generic products, and biosimilars, which could impact revenue growth[50] - There are uncertainties regarding the demand for COVID-19 products, which may lead to reduced revenues and excess inventory[50] - The company is exposed to fluctuations in interest rates and foreign currency exchange rates, which could affect financial performance[50] - Significant issues with major wholesale distributors or government customers could impact a substantial portion of revenues[50] - The company is at risk of legal and regulatory challenges that may affect product pricing and access, particularly in the U.S. and international markets[53] - The potential impact of climate change and natural disasters on operations is a concern for the company[53] - The company is undertaking corporate strategic initiatives that may require upfront costs but could yield unexpected consequences[53] - There are risks associated with the company's ability to achieve climate-related goals and progress in environmental sustainability[53] - The company is facing challenges related to cybersecurity threats, including potential cyber-attacks and data breaches[57] - The company is involved in collaborations for co-research and co-development of products, which may vary by market[56]

Things were going great, right until the point when they weren't.Few would dispute that Pfizer (PFE 0.63%) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $ ...

智通财经4月29日电，辉瑞公司重申2025年全年财务指引的所有组成部分，包括610亿美元至640亿美元 的收入和2.80美元至3.00美元的调整后摊薄后每股收益。 ...

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29. Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share in the year-ago period. Pfizer projects to report quarterly revenue at $14.09 billion, compared to $14.88 billion a year earlier, according to data from Benzinga Pro. Guardant Health GH, on April 24, announced a strategic collaboration with Pfizer to support the developmen ...

Industry Overview - The first-quarter earnings season for the drug and biotech sector is underway, with major companies like Pfizer, Eli Lilly, Amgen, Biogen, and Regeneron set to announce results [1] - Johnson & Johnson and Merck have reported results, both exceeding first-quarter estimates for earnings and sales, while Sanofi had mixed results, beating earnings estimates but missing sales [1] Earnings Trends - As of April 23, 15% of companies in the Medical sector, representing 33.8% of the sector's market capitalization, reported quarterly earnings, with 77.8% surpassing estimates for both earnings and revenues [3] - Year-over-year earnings increased by 4.7%, and revenues rose by 9.4% [3] - Overall, first-quarter earnings for the Medical sector are expected to increase by 35%, while sales are projected to rise by 7.8% compared to the previous year [3] Company Performance Pfizer (PFE) - Pfizer has consistently exceeded earnings expectations in the last four quarters, with an average earnings surprise of 44.16% [5] - The Zacks Consensus Estimate for first-quarter sales and earnings is $13.88 billion and 64 cents per share, respectively [6] - Non-COVID operational revenues are driving growth, supported by products like Vyndaqel, Padcev, and Eliquis, despite a decline in sales of COVID products [7] Eli Lilly (LLY) - Eli Lilly has had mixed performance, exceeding earnings expectations in three of the last four quarters, with an average earnings surprise of 8.47% [8] - The Zacks Consensus Estimate for sales and earnings is $12.62 billion and $3.52 per share, respectively [8] - Growth is expected to be driven by demand for FDA-approved tirzepatide medicines, although sales of Mounjaro and Zepbound were below expectations [9][10] Amgen (AMGN) - Amgen has shown strong performance, beating earnings estimates in each of the last four quarters, with an average earnings surprise of 5.23% [11] - The Zacks Consensus Estimate for first-quarter sales and earnings is $7.96 billion and $4.15 per share, respectively [11] - Product sales are expected to be driven by strong volume growth, although prices may decline due to higher rebates [12] Biogen (BIIB) - Biogen has consistently beaten earnings estimates in the last four quarters, with an average earnings surprise of 11.80% [13] - The Zacks Consensus Estimate for sales and earnings is $2.23 billion and $3.52 per share, respectively [13] - Lower sales of multiple sclerosis drugs are likely to be offset by revenues from new drugs [14] Regeneron (REGN) - Regeneron has had mixed results, surpassing earnings expectations in three of the last four quarters, with an average earnings surprise of 3.23% [16] - The Zacks Consensus Estimate for first-quarter sales and earnings is $3.28 billion and $8.43 per share, respectively [17] - Sales of Eylea are expected to have declined due to competition, but sales of Eylea HD and Dupixent are likely to have surged [18][19]

Market Overview - US stock index futures are all down before the market opens, with Dow futures down 0.06%, S&P 500 futures down 0.12%, and Nasdaq futures down 0.07% [1] - Major European indices show positive performance, with Germany's DAX up 0.52%, UK's FTSE 100 up 0.11%, France's CAC40 up 0.72%, and the Euro Stoxx 50 up 0.50% [2][3] - WTI crude oil is down 0.33% at $62.81 per barrel, while Brent crude oil is down 0.36% at $65.56 per barrel [3][4] Economic Data and Corporate Earnings - The upcoming week is significant for economic data and corporate earnings, with the April non-farm payroll report and Q1 inflation data being key focuses [5] - 180 S&P 500 companies are set to report quarterly earnings, with major companies like Apple, Amazon, Coca-Cola, Eli Lilly, Meta, Microsoft, and Chevron in the spotlight [5] Corporate Actions - Spirit AeroSystems has reached an agreement with Airbus for the acquisition of certain assets, with Boeing repurchasing its previously divested business for $4.7 billion in stock [8] - Merck has announced a $3.9 billion acquisition of SpringWorks Therapeutics to enhance its oncology drug portfolio, with the deal valued at approximately $3.4 billion in enterprise value [9] - Amazon has seen prices of nearly 1,000 products rise by an average of 30% due to the impact of tariffs, affecting various categories from electronics to clothing [10] Earnings Forecast - Upcoming earnings reports include companies such as NXP Semiconductors, AstraZeneca, BP, Novartis, Deutsche Bank, HSBC, Coca-Cola, Pfizer, UPS, General Motors, Daqo New Energy, and JinkoSolar [11]

NO.1 首次明确，打击网络"医托" 国家疾控局等3部门近日联合发布医疗卫生领域《2025年国家随机监督抽查计划》。相较于2024年计 划，2025年计划在监管范围等方面作出调整，新增互联网诊疗、精神卫生等监管领域，并首次明确打击 网络"医托"等新型违法行为，进一步强化公共卫生和医疗秩序治理。 点评：监管明确打击网络"医托"，是医疗监管的有力升级。网络"医托"隐蔽性强，严重干扰医疗秩序、 损害患者权益。配合互联网诊疗等新领域监管，有望净化医疗网络空间。 NO.2 信达生物宣布与奥赛康合作的第三代EGFR TKI肺癌靶向药物一线适应证获批上市 每经记者 甄素静 每经编辑 魏官红 丨 2025年4月28日 星期一 丨 仙琚制药在2024年年报中披露，公司于2025年4月收到行政处罚告知书，公司涉嫌达成垄断并实施垄断 协议，固定和变更地塞米松磷酸钠原料药价格，拟被罚没约2亿元。 《每日经济新闻》记者致电天津市市场监管委，工作人员表示，目前案件仍在处理阶段，尚未作出正式 决定，已向企业送达告知书。 点评：从市场角度看，原料药价格垄断会干扰药品市场的正常秩序，影响其他药企的生产经营。从行业 发展来看，这一事件凸显了监管 ...

Group 1 - Pfizer is expected to release its Q1 earnings soon, presenting a potential investment opportunity with a 7.55% dividend yield [1] - The dividend is considered highly likely to be safe due to Pfizer's stabilizing revenue trajectory [1] Group 2 - The article emphasizes the importance of thorough research and a long-term investment perspective in navigating market cycles [1]

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings est ...

Core Viewpoint - Pfizer is expected to report quarterly earnings of $0.64 per share, reflecting a 22% decline year-over-year, with revenues projected at $13.88 billion, a decrease of 6.7% compared to the previous year [1]. Earnings Estimates - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating a stable outlook among analysts [1]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock [2]. Revenue Projections - Analysts estimate 'Revenues- Oncology- Ibrance- Worldwide' at $898.97 million, down 14.7% from the prior year [4]. - 'Revenue- Specialty Care- Cibinqo' is projected to reach $71.20 million, an increase of 69.5% year-over-year [4]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is expected to be $141.92 million, down 26.9% from the previous year [5]. - 'Revenues- Oncology- Inlyta- Worldwide' is estimated at $207.30 million, indicating a 12.5% decline year-over-year [5]. Regional Revenue Insights - 'Revenues- Oncology- Ibrance- United States' is projected at $565.50 million, down 16.7% from the year-ago quarter [6]. - 'Revenues- Specialty Care- Xeljanz- Total International' is expected to be $101.82 million, reflecting a 15.2% decrease [6]. - 'Revenues- Oncology- Ibrance- Total International' is estimated at $333.47 million, down 11.1% year-over-year [7]. - 'Revenues- Specialty Care- Xeljanz- United States' is projected to be $40.10 million, indicating a significant decline of 45.8% [7]. Additional Revenue Metrics - 'Revenues- Oncology- Inlyta- Total International' is expected to reach $91.42 million, down 4.8% year-over-year [8]. - 'Revenues- Oncology- Inlyta- United States' is projected at $115.88 million, reflecting a 17.8% decline [8]. - 'Revenue- Primary Care- Prevnar family- United States' is estimated at $1.14 billion, a slight decrease of 0.4% from the prior year [9]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to be $550.39 million, indicating a year-over-year increase of 1.6% [9]. Stock Performance - Over the past month, Pfizer shares have returned -11.2%, compared to the Zacks S&P 500 composite's -5.1% [9]. - Pfizer currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [10].